SBP Group (01177.HK) today announced a strategic multi-program option and license agreement with Boehringer Ingelheim to advance potential next-generation cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies. Building on the companies’ existing collaboration in oncology, the agreement will bring together SBP Group’s innovative platforms and early-development capabilities with Boehringer Ingelheim’s global oncology expertise to advance new treatment approaches for patients worldwide.

From October 23 to 27 (local time), the 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain. Studies on 2 investigational products and 3 marketed products from Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), were selected for presentation.

On October 23 (local time), at the 2026 European Society for Medical Oncology (ESMO) Congress, TQB2102, a new-generation HER2 bispecific antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), released the results of a Phase II clinical study evaluating TQB2102 in combination with benmelstobart (TQB2450) ± capecitabine as first-line treatment for HER2-positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC).

On October 23 (local time), at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain, TQB2102, a new-generation HER2 bispecific antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), announced the latest data from the pivotal Phase III clinical study (APEX-Breast01) for the treatment of HER2-low advanced breast cancer.

CTTQ, a core company of SBP Group (01177.HK), will present 21 clinical studies across its oncology portfolio at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

Recently, CTTQ (Chia Tai Tianqing), a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 01177.HK), signed an agreement with the National Natural Science Foundation of China (NSFC) to contribute 100 million RMB to participate in the Joint Fund for Innovation and Development of Private Enterprises of the National Natural Science Foundation (hereinafter referred to as the "Joint Fund").

On September 28, SBP Group (01177.HK) announced that its core subsidiary, Chia Tai Tianqing Pharmaceutical Group (CTTQ), has entered into a strategic biosimilars partnership with STADA Arzneimittel AG (STADA), a leading European healthcare and pharmaceuticals company.

Recently, the marketing applications for two Class 1 therapeutic biologics developed by CTTQ (Chia Tai Tianqing), a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 01177.HK) — TQB2102 for injection and TQH2722 injection — were accepted for review on the same day.

From September 8 to 9, the 2026 Shanghai International Pharma-Health Innovation and Capital Conference and the 15th Pharma CEO Forum were held in Shanghai.

On September 5, the 22nd Summer Summit of the Yabuli China Entrepreneurs Forum (hereinafter referred to as Yabuli Forum) 2026 opened in Chengdu with the theme "Corporate Innovation and Overcoming Cycles".